MSH6 (D60G2) XP[®] Rabbit mAb





Orders:	877-616-CELL (2355) orders@cellsignal.com
Support:	877-678-TECH (8324)
Web:	info@cellsignal.com cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W, IF-IC	Reactivity: H Mk	Sensitivity: Endogenous	MW (kDa): 160	Source/Isotype: Rabbit IgG	UniProt ID: #P52701	Entrez-Gene Id: 2956		
Product Usage Information	2	Application Western Blotting Immunofluorescence	(Immunocytochem	iistry)		Dilution 1:1000 1:50		
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.						
Specificity/Sen	sitivity	MSH6 (D60G2) XP $^{ extsf{B}}$ Rabbit mAb detects endogenous levels of total MSH6 protein.						
Source / Purifi	cation	Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human MSH6.						
Background		The DNA mismatch repair system (MMR) repairs post-replication DNA, inhibits recombination between nonidentical DNA sequences, and induces both checkpoint and apoptotic responses following certain types of DNA damage (1). MSH2 (MutS homologue 2) forms the hMutS-α dimer with MSH6 and is an essential component of the mismatch repair process. hMutS-α is part of the BRCA1-associated surveillance complex (BASC), a complex that also contains BRCA1, MLH1, ATM, BLM, PMS2 proteins, and the Rad50-Mre11-NBS1 complex (2). Mutations in MSH6 and other MMR proteins have been found in a large proportion of hereditary nonpolyposis colorectal cancer (Lynch Syndrome), the most common form of inherited colorectal cancer in the Western world (3). Mutations in MSH6 have been shown to occur in glioblastoma in response to temozolomide therapy and to promote temozolomide resistance (4).						
Background Ro	eferences	1. O'Brien, V. and Brown, R. (2006) <i>Carcinogenesis</i> 27, 682-92. 2. Wang, Y. et al. (2000) <i>Genes Dev</i> 14, 927-39. 3. Plotz, G. et al. (2006) <i>J Mol Histol</i> 37, 271-83. 4. Yip, S. et al. (2009) <i>Clin Cancer Res</i> 15, 4622-9.						
Species Reacti	vity	Species reactivity is determined by testing in at least one approved application (e.g., western blot).						
Western Blot E	Buffer	IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.						
Applications K	ey	W: Western Blotting IF-IC: Immunofluorescence (Immunocytochemistry)						
Cross-Reactivi	ty Key	H: Human Mk: Monkey						
Trademarks ar	nd Patents	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.						
		XP is a registered trademark of Cell Signaling Technology, Inc.						
		All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.						
Limited Uses		the following terms a terms and conditions	pply to Products pro that are in addition	a writing signed by a leg ovided by CST, its affiliat to, or different from, th y authorized representa	es or its distributor ose contained here	s. Any Customer's in, unless		
		approved, cleared, or	licensed by the FDA	se Only or a similar labe or other regulatory for duct for any diagnostic o	eign or domestic er	ntity, for any		

any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products on services that would compete with CST products or services, (c) not alter or remove from the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.